■髌腱炎(PT)是髌腱的一种常见退行性疾病,严重影响了精英运动员的运动生涯和运动爱好者的日常生活活动。注射疗法是PT的普遍侵入性治疗。
■这项工作全面分析了考虑试剂类型和特性的PT的各种注射处理,频率,并通过荟萃分析评估时间点。
■PubMed,Embase,Cochrane图书馆是数据的来源.
■考虑了随机对照试验(RCT),该试验分析了各种注射策略对PT患者治疗的影响。
■系统评价和荟萃分析。
■二级。
■第一作者,出版年份,研究地点,注册信息,患者类型,样本量,年龄,性别,干预,对照治疗,并提取每个研究的随访期。
■19项随机对照试验包括在分析中。在维多利亚州体育评估学院髌骨(VISA-P)结果的网络荟萃分析中,脊髓灰质炎(标准化平均差(SMD),6.52;95%CI4.75,8.30;P<0.01),肌腱样细胞(SMD,4.08;95%CI2.92,5.25;P<0.01),和缺乏白细胞的富血小板血浆(LP-PRP)加高容量图像引导注射(HVIGI)(SMD,1.56;95%CI0.62,2.50;P<0.01)显著优于非注射保守治疗,主要是在6个月的随访时间点。对于可视化模拟量表结果,多次干针刺(DN)(SMD,-1.78;95%CI-2.56,-1.00;P<0.01),LP-PRP(SMD,-0.71;95%CI-1.31,-0.12;P=0.02),和LP-PRP加HVIGI(SMD,-1.31;95%CI-2.22,-0.39;P<0.01)显著优于空白,这也主要是在6个月的时间点。
■注射相关治疗:脊髓灰质炎,肌腱样细胞,LP-PRP,和多个DN显示出潜在的短期(1-3个月)或中期(6个月)治疗益处。仍然没有证据表明注射干预具有长期治疗益处。
UNASSIGNED: Patellar tendonitis (PT) is a common degenerative disease of the patellar tendon that seriously affects the sports careers of elite athletes and activities of daily living of sports enthusiasts.
Injection therapy is a prevalent invasive treatment for PT.
UNASSIGNED: This work comprehensively analyzes various
injection treatments for PT that consider agent type and characteristics, frequency, and assessment timepoints by meta-analysis.
UNASSIGNED: PubMed, Embase, and the Cochrane Library were sources of data.
UNASSIGNED: Randomized controlled trials (RCTs) analyzing the effect of various
injection strategies on the treatment of patients with PT were considered.
UNASSIGNED: Systematic review and meta-analysis.
UNASSIGNED: Level 2.
UNASSIGNED: First author, year of publication, research location, registration information, patient type, sample size, age, sex, intervention, control treatment, and follow-up period in each study were extracted.
UNASSIGNED: Nineteen RCTs were included in the analysis. In the network meta-analysis of Victorian Institute of Sports Assessment-Patellar (VISA-P) outcomes, polidocanol (standardized mean difference (SMD), 6.52; 95% CI 4.75, 8.30; P < 0.01), tenocyte-like cells (SMD, 4.08; 95% CI 2.92, 5.25; P < 0.01), and leukocyte-poor platelet-rich plasma (LP-PRP) plus high-volume image-guided injection (HVIGI) (SMD, 1.56; 95% CI 0.62, 2.50; P < 0.01) were significantly superior to noninjection conservative treatment, mainly at the 6-month follow-up timepoint. For visual analog scale results, multiple dry needling (DN) (SMD, -1.78; 95% CI -2.56, -1.00; P < 0.01), LP-PRP (SMD, -0.71; 95% CI -1.31, -0.12; P = 0.02), and LP-PRP plus HVIGI (SMD, -1.31; 95% CI -2.22, -0.39; P < 0.01) were significantly superior to blank, which was also mainly at the 6-month timepoint.
UNASSIGNED: Injection-related treatments: polidocanol, tenocyte-like cells, LP-PRP, and multiple DN showed potential short (1-3 months) or medium (6 months)-term treatment benefits. There is still no evidence for
injection interventions with long-term therapeutic benefit.